Oxford & AstraZeneca pause COVID-19 trial as participant falls ill
Phase 3 clinical trials for the COVID-19 vaccine named AZD1222, developed by AstraZeneca and Oxford University, have been paused after
Read morePhase 3 clinical trials for the COVID-19 vaccine named AZD1222, developed by AstraZeneca and Oxford University, have been paused after
Read moreNestlé’s nutritional science brand Nestlé Health Science (NHSc) furthers efforts of food allergy prevention through the acquisition of California-based biopharmaceutical
Read moreBiotechnology has spearheaded the healthcare industry in investment action from private equity and venture capital during the first half of
Read moreEli Lilly and Company announced the start of BLAZE-2, a Phase 3 study of the monoclonal antibody LY-CoV555 vaccine candidate
Read moreSanofi and GSK are in preliminary talks with the European Commission (EC) on the supply of up to 300 million
Read moreResults from the ongoing Phase I/II COVID-19 vaccine trial, led by the University of Oxford, showed the AZD1222 vaccine developed
Read moreModerna’s COVID-19 vaccine candidate generated antibodies in all 45 patients studied in its early stage human trial, the U.S biotech
Read moreSanofi and GlaxoSmithKline are close to reaching a 500 million-pound ($624 million) deal to supply the United Kingdom government with
Read moreThese three pharmaceutical companies should be well shielded from the adverse effects of the looming economic downturn. According to the
Read moreThe World Health Organization (WHO) and the Democratic Republic of Congo (DRC) government announced on June 25 that the second-largest
Read more